Objective To discuss the change of sympathetic skin response (SSR) in patients with cerebral thrombosis with no more than 60 years old. Method SSR was measured in four positions of the center of hand palm and foot palm of 40 normal controls ( control group ) and 56 cerebral thrombosis patients (cerebral thrombosis group) no more than 60 years old. Results SSR wave shape was all educed in control group,but 21 limbs (21/224,9.4%) were not educed in cerebral thrombosis group, SSR abnormality was 80 limbs (35.7% ). SSR's latency in cerebral thrombosis group was obviously prolonged as compared with control group,and the amplitudes of SSR of upper limps and lower limbs had significance between two groups (P< 0.05 or < 0.01). There were serious abnormity within 3 days to 2 months after cerebral thrombosis. Conclusion SSR is a sensitive diagnosis method for the autonomic neuropathy of cerebral thrombosis patients of no more than 60 years old.

OBJECTIVE: To investigate the extent of the cross-reactivity of hybrid capture 2 (HC2) assay and evaluate the potential effect of cross-reactivity on the long-term risk for cervical cancer and precancers. METHODS: Based on the Shanxi Province Cervical Cancer Screening Study-I (SPOCCS-I) cohort from 2005 to 2014 in Shanxi, China, SPF₁₀-line probe assay (LiPA) was performed in all 598 HC2 positive and 300 random-selected HC2 negative cervical specimens. Ten-year cumulative incidence rate (CIR) of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) of these two tests was evaluated using Kaplan-Meier methods. Possible human papillomavirus (HPV) types to be cross-reacted by HC2 were also analyzed. RESULTS: The overall agreement between HC2 and SPF₁₀-LiPA for detecting carcinogenic HPV was 73.27%. The highest 10-year cumulative risk of CIN2+ was observed in both HC2 positive and LiPA-carcinogenic HPV positive women (25.70%; 95% confidence interval [CI]=23.55%–27.91%), followed by HC2 positive but LiPA-non-carcinogenic HPV positive women (9.97%; 95% CI=8.57%–11.50%), HC2 negative but LiPA-carcinogenic HPV positive (2.56%; 95% CI=2.44%–2.70%) and HC2 positive but LiPA-HPV negative (1.85%; 95% CI=1.78%–1.92%) women. The proportion of cross-reactivity of HC2 with untargeted carcinogenic types was 8.9%, most of which were attributable to HPV26, 73, 82, 69, 71, 53, 11, 43, and 54. CONCLUSION: The noticeable high risk of CIN2+ in women infected with cross-reacted non-carcinogenic HPV and low risk in those with miss-to-detective carcinogenic HPV supported an overall good clinical performance of HC2 for a general cervical cancer screening.
Cervical Intraepithelial Neoplasia ; China* ; Cohort Studies* ; Female ; Humans* ; Incidence ; Mass Screening ; Prospective Studies* ; Uterine Cervical Neoplasms*